Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 139Terminated 41Recruiting 32Active not recruiting 24Unknown 16Not yet recruiting 12Withdrawn 5

Sponsor Class

OTHER 27INDUSTRY 5OTHER_GOV 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1CNS 1

Conditions

Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Irinotecan × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00577109 2018-07-31

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Hoffmann-La Roche

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT01070290 2014-01-07

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Withdrawn
Gastrointestinal

Stomach Neoplasms

NCT00233623 2011-01-27

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

AstraZeneca

Phase 2 Withdrawn
190 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡